All Stories

  1. Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report
  2. Cardiac xenotransplantation in a human
  3. The immunobiology and clinical use of genetically engineered porcine hearts for cardiac xenotransplantation
  4. Genetically Modified Porcine-to-Human Cardiac Xenotransplantation
  5. Progressive genetic modifications of porcine cardiac xenografts extend survival to 9 months
  6. Cardiac Xenotransplantation: Progress in Preclinical Models and Prospects for Clinical Translation
  7. Blood Cardioplegia Induction, Perfusion Storage and Graft Dysfunction in Cardiac Xenotransplantation
  8. Heterotopic Porcine Cardiac Xenotransplantation in the Intra-Abdominal Position in a Non-Human Primate Model
  9. Early Experience With Preclinical Perioperative Cardiac Xenograft Dysfunction in a Single Program
  10. Intra-Abdominal Heterotopic Cardiac Xenotransplantation: Pearls and Pitfalls
  11. Xenotransplantation: A Step Closer to Clinical Reality?
  12. Cardiac xenografts show reduced survival in the absence of transgenic human thrombomodulin expression in donor pigs
  13. Circulating cell-free DNA as a biomarker of tissue injury: Assessment in a cardiac xenotransplantation model
  14. Consideration of appropriate clinical applications for cardiac xenotransplantation
  15. CD4+CD25Hi FoxP3+ regulatory T cells in long-term cardiac xenotransplantation
  16. Encouraging experience using multi-transgenic xenografts in a pig-to-baboon cardiac xenotransplantation model
  17. Selection of Patients for Initial Clinical Trials of Solid Organ Xenotransplantation
  18. Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft
  19. Early graft failure of GalTKO pig organs in baboons is reduced by expression of a human complement pathway‐regulatory protein
  20. Genetically engineered pigs and target-specific immunomodulation provide significant graft survival and hope for clinical cardiac xenotransplantation
  21. Regulatory T cells enhance mesenchymal stem cell survival and proliferation following autologous cotransplantation in ischemic myocardium
  22. Overexpression of FABP3 inhibits human bone marrow derived mesenchymal stem cell proliferation but enhances their survival in hypoxia
  23. One-Year Heterotopic Cardiac Xenograft Survival in a Pig to Baboon Model
  24. Role of anti-CD40 antibody-mediated costimulation blockade on non-Gal antibody production and heterotopic cardiac xenograft survival in a GTKO.hCD46Tg pig-to-baboon model
  25. Ex-vivo expanded baboon CD4+ CD25Hi Treg cells suppress baboon anti-pig T and B cell immune response
  26. B-Cell Depletion Extends the Survival of GTKO.hCD46Tg Pig Heart Xenografts in Baboons for up to 8 Months
  27. Left Ventricular Pressure Measurement by Telemetry Is an Effective Means to Evaluate Transplanted Heart Function in Experimental Heterotopic Cardiac Xenotransplantation
  28. Surgical and Nonsurgical Complications of a Pig to Baboon Heterotopic Heart Transplantation Model
  29. Rapid and dynamic alterations of gene expression profiles of adult porcine bone marrow-derived stem cell in response to hypoxia
  30. Rapamycin Promotes the Enrichment of CD4+CD25hiFoxP3+ T Regulatory Cells From Naïve CD4+ T Cells of Baboon That Suppress Antiporcine Xenogenic Response In Vitro
  31. Characterization and expansion of baboon CD4+CD25+Treg cells for potential use in a non-human primate xenotransplantation model
  32. Glycolipid antigen induces long-term natural killer T cell anergy in mice
  33. The natural killer T?cell ligand ?-galactosylceramide prevents or promotes pristane-induced lupus in mice
  34. Quantitative and Qualitative Differences in the In Vivo Response of NKT Cells to Distinct α- and β-Anomeric Glycolipids
  35. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion
  36. Immunoregulatory Role of CD1d in the Hydrocarbon Oil-Induced Model of Lupus Nephritis
  37. Immunotherapy with ligands of natural killer T cells
  38. Natural Killer T Cell Activation Protects Mice Against Experimental Autoimmune Encephalomyelitis
  39. Age and gender discrepancies in living related renal transplant donors and recipients
  40. Donor specific CDC lymphocyte crossmatch and five year allograft survival
  41. In vitro pretransplant mixed lymphocyte culture response and acute rejection episodes
  42. Long-term allograft survival in renal transplantation from elderly donors